Lapin and Ebels 1976 paper was one of the first to outline these properties, and subsequent studies have provided further clarification on the molecular basis for melatonins efficient tissue penetration and cellular accessibility (Lapin and Ebels 1976)
Some clinicians recommend microdosing tirzepatide as a maintenance strategy after achieving target weight
In contrast, Wegovy drug is specifically indicated for weight loss
The research fueling these claims includes studies that found semaglutide users may face a significantly higher risk of developing NAION compared to patients using other medications
Stimulation of Lipolysis (The Push): It upregulates Beta-3 Adrenergic Receptors (3-AR) on fat cells, enhancing the sensitivity to endogenous fat-burning signals
WADA status BPC-157 BPC-157 has no approval from any governmental regulatory health authority for human therapeutic use, and as such falls under WADA category S0 (Non-Approved Substances), prohibited at all times (ref
